IDEXX Laboratories (IDXX) Q3 FY2026 Earnings Call

Bottom line

The sleeper story is that IDEXX just cut its own margin-expansion target for the year (70-90bps down to 50-70bps) while the market cheers a revenue and EPS raise, and comparable operating margin growth has already decelerated from +110bps to +60bps intra-year. The obvious headline, 10% organic growth and a beat-and-raise quarter, is real, but it's increasingly an international story (14% growth, accelerating) papering over a decelerating US core (9.6%, visits down 1.8% and getting worse). The binding constraint isn't demand, it's disclosure discipline: when pushed on CancerDx recurring usage, management flatly said they don't split that out further, and when pushed on 2027 Covet dilution, the CFO pivoted to managing it as a portfolio rather than giving a number. My view changes if next quarter they either (a) move the InView revenue-per-analyzer range off $3,500-$5,500 now that FNA is fully launched, or (b) give a specific 2027 operating-margin bps impact from Covet; either would convert today's narrative into a binder and materially improve conviction in the 2027 setup.

The 30-second version

The margin guide got quietly cut while everyone celebrates the raise
Beat-and-raise headline masks a US-core that's losing share of the growth story to international
Two flagship metrics quietly stopped telling you anything useful

What changed this quarter

Metric	Q2'26	Q3'26	Change
Organic revenue growth	9% organic	10% organic	+100bps acceleration
CAG Diagnostics recurring revenue (organic)	10.3%	11%	+70bps acceleration
US CAG Dx recurring revenue (organic)	nearly 10%	9.6%	deceleration domestically
International CAG Dx recurring revenue (organic)	nearly 12%	14%	+200bps acceleration, now the growth engine
US same-store clinical visits	-1.3%	-1.8%	Worsened vs. guided -1.5% assumption
Reported EPS	$4.27, +18% reported / +15% comparable	$4.01, +18% reported / +22% comparable	Sequential dollar decline but cleaner comparable beat
Comparable operating margin YoY change	+110bps	+60bps	Margin expansion decelerating
Gross margin (reported)	64%, +120bps comparable	62.9%, +90bps comparable	Down 110bps sequentially
FY operating margin guide	32.3%-32.5%	32.1%-32.3%	Guide cut despite revenue/EPS raise
FY capital expenditure guide	~$180M	~$160M	Cut $20M, unexplained

Accountability tracked

2 new promises made5 narrative shifts flagged3 prior promises scored

Inside the full report

The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.

Read the full IDXX Q3'26 report Subscribe

IDEXX Laboratories (IDXX)

The 30-second version

What changed this quarter

Accountability tracked

Follow what management promises next